Academic literature on the topic 'Population-based cancer registry'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Population-based cancer registry.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Journal articles on the topic "Population-based cancer registry"
1
Opoku, P. "Establishing Accra Population-Based Cancer Registry." Journal of Global Oncology 4, Supplement 2 (October 1, 2018): 66s. http://dx.doi.org/10.1200/jgo.18.64600.
Full textAbstract:
Background: The African Cancer Organization (ACO) seeks to establish Accra Population-Based Cancer Registry (ACR). The whole idea is to collect, store and analyze data on persons with cancer to provide complete, accurate and timely cancer report for interventional programs. Such information would guide us to monitor patient care, prioritize and allocate resources effectively, give understanding of the things we do not yet know, and also act as a driver for policy development for the urgent need of comprehensive cancer control in Ghana. Countries require cancer surveillance programs to collect and analyze data on the scale of the cancer burden in each country. These are urgently needed in Africa as cancer data sources are scarce. Data can help to evaluate the impact of prevention, early detection/screening, treatment and palliative care programs. The proposed population-based cancer registry will help to act as a driver for policy development and program evaluation as recommended by the WHO. ACR intends to capture cancer cases diagnosed and/or treated within the Greater Accra region of Ghana and then further extend to cover the Central, Eastern, Western and the Volta regions of Ghana later. Aim: The goal of ACR to collect, store and analyze data on persons with cancer to generate incidence, prevalence, trends, mortality, and survival rates which is required to help develop a realistic and sustainable cancer control plan for Ghana. Methods: Cancer registry staff will be trained to abstract cancer cases diagnosed and/or treated within the southern regional geography of Ghana using a customized cancer notification form designed to capture detailed information on cancer patient demographics, tumor details, treatment, reporting sources and follow-up information based on both analytic and nonanalytic active case-finding reportability methods. These cases will then be classified and coded using the ICD-O-3, FIGO and/or SEER Summary Staging 2000 Manual. The data will be stored in customized cancer registry software which will be configured with various address codes from the registry geography. The cancer registry software checks for duplicate cases, data edits and consolidation. The software tracks down duplicate records and multiple primaries using a probability matching and consistency checking for impossible or rare cases. Conclusion: Establishing a cancer registry in Africa is challenging but very possible. Conflicts of interests are common norms among new cancer registries. With a good budget and working plan backed by few sincere and dedicated staff, it will be very possible to sustain the registry to capture all cancer cases within the catchment area, to take advantage of available modern technology to produce timely results. ACO is by this seeking for partnership to raise the needed support to embark on this national cancer registry campaign in the region.
2
Polednak, Anthony P. "Familial Testicular Cancer in a Population-Based Cancer Registry." Urologia Internationalis 56, no. 4 (1996): 238–40. http://dx.doi.org/10.1159/000282850.
Full text
3
Subedi, Ranjeeta, Meghnath Dhimal, Atul Budukh, Pradeep Gyawali, and Anjani Kumar Jha. "Challenges and Way Forward for Establishing Population Based Cancer Registry in Nepal." Journal of Nepal Health Research Council 18, no. 3 (November 14, 2020): 544–46. http://dx.doi.org/10.33314/jnhrc.v18i3.2703.
Full textAbstract:
Population Based Cancer Registry plays a crucial role in cancer control through identifying cancer incidence, mortality, pattern and trends over time in a particular population. The registry is in a very infancy stage in Nepal. During the process of establishing Population Based Cancer Registry in Nepal, the major challenges include adequate coverage of the cases, high cost of registration, sustainability along with expansion of the registry to other regions and non-linkage of Hospital Based Cancer Registry with Population Based Cancer Registry. However, the approach of mobilization of field enumerators at the end of year once had increased coverage of the cases. Similarly, the linkage of Population Based Cancer Registry with the existing Health Management and Information System will help in developing sustainable Population Based Cancer Registry and also provides an opportunity to increase coverage and expand it to other districts as well.
Keywords: Challenges; Nepal; population based cancer registry; way forward
4
Syse, Astri, Jon H. Loge, and Torkild H. Lyngstad. "Does Childhood Cancer Affect Parental Divorce Rates? A Population-Based Study." Journal of Clinical Oncology 28, no. 5 (February 10, 2010): 872–77. http://dx.doi.org/10.1200/jco.2009.24.0556.
Full textAbstract:
Purpose Cancer in children may profoundly affect parents' personal relationships in terms of psychological stress and an increased care burden. This could hypothetically elevate divorce rates. Few studies on divorce occurrence exist, so the effect of childhood cancers on parental divorce rates was explored. Patients and Methods Data on the entire Norwegian married population, age 17 to 69 years, with children age 0 to 20 years in 1974 to 2001 (N = 977,928 couples) were retrieved from the Cancer Registry, the Central Population Register, the Directorate of Taxes, and population censuses. Divorce rates for 4,590 couples who were parenting a child with cancer were compared with those of otherwise similar couples by discrete-time hazard regression models. Results Cancer in a child was not associated with an increased risk of parental divorce overall. An increased divorce rate was observed with Wilms tumor (odds ratio [OR], 1.52) but not with any of the other common childhood cancers. The child's age at diagnosis, time elapsed from diagnosis, and death from cancer did not influence divorce rates significantly. Increased divorce rates were observed for couples in whom the mothers had an education greater than high school level (OR, 1.16); the risk was particularly high shortly after diagnosis, for CNS cancers and Wilms tumors, for couples with children 0 to 9 years of age at diagnosis, and after a child's death. Conclusion This large, registry-based study shows that cancer in children is not associated with an increased parental divorce rate, except with Wilms tumors. Couples in whom the wife is highly educated appear to face increased divorce rates after a child's cancer, and this may warrant additional study.
5
Memirie, Solomon Tessema, Mahlet Kifle Habtemariam, Mathewos Asefa, Biniyam Tefera Deressa, Getamesay Abayneh, Biniam Tsegaye, Mihiret Woldetinsae Abraha, et al. "Estimates of Cancer Incidence in Ethiopia in 2015 Using Population-Based Registry Data." Journal of Global Oncology, no. 4 (December 2018): 1–11. http://dx.doi.org/10.1200/jgo.17.00175.
Full textAbstract:
Purpose Noncommunicable diseases, prominently cancer, have become the second leading cause of death in the adult population of Ethiopia. A population-based cancer registry has been used in Addis Ababa (the capital city) since 2011. Availability of up-to-date estimates on cancer incidence is important in guiding the national cancer control program in Ethiopia. Methods We obtained primary data on 8,539 patients from the Addis Ababa population-based cancer registry and supplemented by data on 1,648 cancer cases collected from six Ethiopian regions. We estimated the number of the commonest forms of cancer diagnosed among males and females in Ethiopia and computed crude and age-standardized incidence rates. Results For 2015 in Ethiopia, we estimated that 21,563 (95% CI, 17,416 to 25,660) and 42,722 (95% CI, 37,412 to 48,040) incident cancer cases were diagnosed in males and females, respectively. The most common adult cancers were: cancers of the breast and cervix, colorectal cancer, non-Hodgkin lymphoma, leukemia, and cancers of the prostate, thyroid, lung, stomach, and liver. Leukemia was the leading cancer diagnosis in the pediatric age group (age 0 to 14 years). Breast cancer was by far the commonest cancer, constituting 33% of the cancers in women and 23% of all cancers identified from the Addis Ababa cancer registry. It was also the commonest cancer in four of the six Ethiopian regions included in the analysis. Colorectal cancer and non-Hodgkin lymphoma were the commonest malignancies in men. Conclusion Cancer, and more prominently breast cancer, poses a substantial public health threat in Ethiopia. The fight against cancer calls for expansion of population-based registry sites to improve quantifying the cancer burden in Ethiopia and requires both increased investment and application of existing cancer control knowledge across all segments of the Ethiopian population.
6
Maglakelidze, M., M. Abuladze, N. Jokhadze, and D. Maglakelidze. "Implementation of Population-Based Cancer Registry in Georgia: Results of the Appeared Requirements to NCCP." Journal of Global Oncology 4, Supplement 2 (October 1, 2018): 154s. http://dx.doi.org/10.1200/jgo.18.92000.
Full textAbstract:
Background: The current cancer patterns in Georgia indicate that a significant proportion of cancer cases and deaths are preventable if appropriate actions are undertaken. The estimates from IARC indicate 12,361 new cancer cases per annum in 2012. The estimated number of deaths from cancer in 2012 was 7319. Objectives: The aim of the project was to: Implement modern cancer registration system in Georgia; Ensure compliance of reporting standards; Create registry that will meet international data standards; Reveal the main national trends of incidence and mortality in Georgia. Methods: In 2011-2014 as a result of active work with Ministry of Health Care (MOH) preliminary actions were taken under the State Program of Modern Cancer Registry Implementation, including: translation and publishing of ICD-O-3; translation of CanReg5 software and training of registrars; translation and filling of dictionaries: topography, morphology, administrative units, and institutions providing oncology services; participation in international training and courses organized by International Agency for Research on Cancer (IARC). Results: According to the schedule I stage of the program has been completed successfully. New model of cancer registry has been developed The first results of the register are received 8731 new cases of cancer have been diagnosed in Georgia in 2017 (234.8-291.6 per 100,000). Incidence of almost every type of cancer (in all localizations) is less than the incidence in European region and in EU countries. This number is closer to the CIS average data. Almost all localization cancer incidence in both men and women is less compared with the indicators of the European region and EU countries and is closer to the CIS average data. Collectively accounting for > 60% of all new cancers and half of all cancer deaths. Second most common cancer type in registered new cases among females is thyroid cancer. From 2015 there is a gradual increase in newly registered cases of thyroid cancer and its incidence among 100,000 females (2015 - 33.5, 2016 - 42.8, 2017 - 40. In 2017, there was 55 new thyroid cancer cases among females younger than 25 years (in 2015 this number was 41, in 2016 -50); this number corresponds to 50% of all newly registered cancer cases among this age group. By the end of the next year Cancer Registry will be linked to EMR notification system that itself will be linked to public and death registry and data on every cancer patient will automatically appear in the cancer registry database. Conclusion: Developed model of Cancer Registry will serve as a basis for clinical, epidemiologic, and health care services research and for the assessment of their efficacy in Georgia.
7
Chapagain, Sandhya, Atul Budukh, Ganesh Dangal, and Anjani Kumar Jha. "Initiation of Population-based Cancer Registry in Nepal." Journal of Nepal Health Research Council 17, no. 3 (November 13, 2019): I—II. http://dx.doi.org/10.33314/jnhrc.v17i3.2359.
Full text
8
Parkin, Donald M. "The evolution of the population-based cancer registry." Nature Reviews Cancer 6, no. 8 (August 2006): 603–12. http://dx.doi.org/10.1038/nrc1948.
Full text
9
Roder, David, Nicola Creighton, Deborah Baker, Richard Walton, Sanchia Aranda, and David Currow. "Changing roles of population-based cancer registries in Australia." Australian Health Review 39, no. 4 (2015): 425. http://dx.doi.org/10.1071/ah14250.
Full textAbstract:
Registries have key roles in cancer incidence, mortality and survival monitoring and in showing disparities across the population. Incidence monitoring began in New South Wales in 1972 and other jurisdictions soon followed. Registry data are used to evaluate outcomes of preventive, screening, treatment and support services. They have shown decreases in cancer incidence following interventions and have been used for workforce and other infrastructure planning. Crude markers of optimal radiotherapy and chemotherapy exist and registry data are used to show shortfalls against these markers. The data are also used to investigate cancer clusters and environmental concerns. Survival data are used to assess service performance and interval cancer data are used in screening accreditation. Registries enable determination of risk of multiple primary cancers. Clinical quality registries are used for clinical quality improvement. Population-based cancer registries and linked administrative data complement clinical registries by providing high-level system-wide data. The USA Commission on Cancer has long used registries for quality assurance and service accreditation. Increasingly population-based registry data in Australia are linked with administrative data on service delivery to assess system performance. Addition of tumour stage and other prognostic indicators is important for these analyses and is facilitated by the roll-out of structured pathology reporting. Data linkage with administrative data, following checks on the quality of these data, enables assessment of patterns of care and other performance indicators for health-system monitoring. Australian cancer registries have evolved and increasingly are contributing to broader information networks for health system management.
10
Motsuku, L., E. Chokunonga, M. Sengayi, E. Singh, L. Khoali, and M. Borok. "Strengthening African Population-Based Cancer Registration Through Regional Mentorship: UICC Fellowship Experience at Zimbabwe National Cancer Registry." Journal of Global Oncology 4, Supplement 2 (October 1, 2018): 65s. http://dx.doi.org/10.1200/jgo.18.68200.
Full textAbstract:
Background: South Africa (SA) recently established an urban population-based cancer registry in Ekurhuleni metropolitan district in Gauteng Province. The Ekurhuleni Population-Based Cancer Registry (EPBCR) aims to inform cancer policy and comprehensive cancer control programs. The registry covers 3.5 million residents including public/private, rural/urban patients and a mix of the multiethnic SA population. The first complete year's data will be published in April 2018. It is crucial that high-quality data collected by newly established registries are comparable regionally and globally. The Union for International Cancer Control (UICC) fellowship provides a practical opportunity for South African National Cancer Registry staff to learn from the Zimbabwe National Cancer Registry (ZNCR), a well-established population-based registry in the region. Aim: To enhance the SA EPBCR through observation and application of methods for population-based cancer registration used at the ZNCR. Methods: A desktop review of published and unpublished articles/reports of the ZNCR was conducted. Semi-structured informal interviews were conducted with registry staff to understand data processes from case finding to reporting. Representative data sources were visited to understand case-finding processes. Results: The ZNCR was established in 1985 through a collaborative research agreement between the Ministry of Health (MoH) and International Agency for Research on Cancer (IARC). Its activities are overseen by a 17-member constituted multidisciplinary advisory committee. The registry staff comprise one registrar, one executive assistant (EA) and four health information assistants (HIA). The process of ensuring quality data are guided by the African Cancer Registry Network and the International Association of Cancer Registries standards for population-based cancer registries. The ZNCR uses a combination of active and passive case-finding methods where HIAs have unrestricted access to patient information in private and public sectors such as hospitals, pathology laboratories, radiotherapy centers and death registries. HIAs conduct patient interviews for accurate demographics and to complete missing information. Cases are coded according to International Classification of Diseases for Oncology-V3 and Canreg software is used for data entry, quality control and analysis. The hard copies are stored in locked cabinets in offices with restricted access. The data are then used for reporting and research. Conclusion: The support of government, commitment of advisory committee volunteers, highly trained and experienced staff are key elements behind the success of ZNCR. Strict adherence to international practices for population-based cancer registration has enabled ZNCR to produce high-quality data for research and cancer programs. The processes used by ZNCR will be customised and implemented at EPBCR.
Dissertations / Theses on the topic "Population-based cancer registry"
1
Yu, Xue Qin. "Comparing survival from cancer using population-based cancer registry data - methods and applications." Thesis, The University of Sydney, 2007. http://hdl.handle.net/2123/1774.
Full textAbstract:
Over the past decade, population-based cancer registry data have been used increasingly worldwide to evaluate and improve the quality of cancer care. The utility of the conclusions from such studies relies heavily on the data quality and the methods used to analyse the data. Interpretation of comparative survival from such data, examining either temporal trends or geographical differences, is generally not easy. The observed differences could be due to methodological and statistical approaches or to real effects. For example, geographical differences in cancer survival could be due to a number of real factors, including access to primary health care, the availability of diagnostic and treatment facilities and the treatment actually given, or to artefact, such as lead-time bias, stage migration, sampling error or measurement error. Likewise, a temporal increase in survival could be the result of earlier diagnosis and improved treatment of cancer; it could also be due to artefact after the introduction of screening programs (adding lead time), changes in the definition of cancer, stage migration or several of these factors, producing both real and artefactual trends. In this thesis, I report methods that I modified and applied, some technical issues in the use of such data, and an analysis of data from the State of New South Wales (NSW), Australia, illustrating their use in evaluating and potentially improving the quality of cancer care, showing how data quality might affect the conclusions of such analyses. This thesis describes studies of comparative survival based on population-based cancer registry data, with three published papers and one accepted manuscript (subject to minor revision). In the first paper, I describe a modified method for estimating spatial variation in cancer survival using empirical Bayes methods (which was published in Cancer Causes and Control 2004). I demonstrate in this paper that the empirical Bayes method is preferable to standard approaches and show how it can be used to identify cancer types where a focus on reducing area differentials in survival might lead to important gains in survival. In the second paper (published in the European Journal of Cancer 2005), I apply this method to a more complete analysis of spatial variation in survival from colorectal cancer in NSW and show that estimates of spatial variation in colorectal cancer can help to identify subgroups of patients for whom better application of treatment guidelines could improve outcome. I also show how estimates of the numbers of lives that could be extended might assist in setting priorities for treatment improvement. In the third paper, I examine time trends in survival from 28 cancers in NSW between 1980 and 1996 (published in the International Journal of Cancer 2006) and conclude that for many cancers, falls in excess deaths in NSW from 1980 to 1996 are unlikely to be attributable to earlier diagnosis or stage migration; thus, advances in cancer treatment have probably contributed to them. In the accepted manuscript, I described an extension of the work reported in the second paper, investigating the accuracy of staging information recorded in the registry database and assessing the impact of error in its measurement on estimates of spatial variation in survival from colorectal cancer. The results indicate that misclassified registry stage can have an important impact on estimates of spatial variation in stage-specific survival from colorectal cancer. Thus, if cancer registry data are to be used effectively in evaluating and improving cancer care, the quality of stage data might have to be improved. Taken together, the four papers show that creative, informed use of population-based cancer registry data, with appropriate statistical methods and acknowledgement of the limitations of the data, can be a valuable tool for evaluating and possibly improving cancer care. Use of these findings to stimulate evaluation of the quality of cancer care should enhance the value of the investment in cancer registries. They should also stimulate improvement in the quality of cancer registry data, particularly that on stage at diagnosis. The methods developed in this thesis may also be used to improve estimation of geographical variation in other count-based health measures when the available data are sparse.
2
Yu, Xue Qin. "Comparing survival from cancer using population-based cancer registry data - methods and applications." University of Sydney, 2007. http://hdl.handle.net/2123/1774.
Full textAbstract:
Doctor of PhilosophyOver the past decade, population-based cancer registry data have been used increasingly worldwide to evaluate and improve the quality of cancer care. The utility of the conclusions from such studies relies heavily on the data quality and the methods used to analyse the data. Interpretation of comparative survival from such data, examining either temporal trends or geographical differences, is generally not easy. The observed differences could be due to methodological and statistical approaches or to real effects. For example, geographical differences in cancer survival could be due to a number of real factors, including access to primary health care, the availability of diagnostic and treatment facilities and the treatment actually given, or to artefact, such as lead-time bias, stage migration, sampling error or measurement error. Likewise, a temporal increase in survival could be the result of earlier diagnosis and improved treatment of cancer; it could also be due to artefact after the introduction of screening programs (adding lead time), changes in the definition of cancer, stage migration or several of these factors, producing both real and artefactual trends. In this thesis, I report methods that I modified and applied, some technical issues in the use of such data, and an analysis of data from the State of New South Wales (NSW), Australia, illustrating their use in evaluating and potentially improving the quality of cancer care, showing how data quality might affect the conclusions of such analyses. This thesis describes studies of comparative survival based on population-based cancer registry data, with three published papers and one accepted manuscript (subject to minor revision). In the first paper, I describe a modified method for estimating spatial variation in cancer survival using empirical Bayes methods (which was published in Cancer Causes and Control 2004). I demonstrate in this paper that the empirical Bayes method is preferable to standard approaches and show how it can be used to identify cancer types where a focus on reducing area differentials in survival might lead to important gains in survival. In the second paper (published in the European Journal of Cancer 2005), I apply this method to a more complete analysis of spatial variation in survival from colorectal cancer in NSW and show that estimates of spatial variation in colorectal cancer can help to identify subgroups of patients for whom better application of treatment guidelines could improve outcome. I also show how estimates of the numbers of lives that could be extended might assist in setting priorities for treatment improvement. In the third paper, I examine time trends in survival from 28 cancers in NSW between 1980 and 1996 (published in the International Journal of Cancer 2006) and conclude that for many cancers, falls in excess deaths in NSW from 1980 to 1996 are unlikely to be attributable to earlier diagnosis or stage migration; thus, advances in cancer treatment have probably contributed to them. In the accepted manuscript, I described an extension of the work reported in the second paper, investigating the accuracy of staging information recorded in the registry database and assessing the impact of error in its measurement on estimates of spatial variation in survival from colorectal cancer. The results indicate that misclassified registry stage can have an important impact on estimates of spatial variation in stage-specific survival from colorectal cancer. Thus, if cancer registry data are to be used effectively in evaluating and improving cancer care, the quality of stage data might have to be improved. Taken together, the four papers show that creative, informed use of population-based cancer registry data, with appropriate statistical methods and acknowledgement of the limitations of the data, can be a valuable tool for evaluating and possibly improving cancer care. Use of these findings to stimulate evaluation of the quality of cancer care should enhance the value of the investment in cancer registries. They should also stimulate improvement in the quality of cancer registry data, particularly that on stage at diagnosis. The methods developed in this thesis may also be used to improve estimation of geographical variation in other count-based health measures when the available data are sparse.
3
Nguyen, Hoang Minh Dung. "Information Extraction from Radiology Reports for a Population Based Cancer Registry." Thesis, The University of Sydney, 2013. http://hdl.handle.net/2123/9466.
Full textAbstract:
In a noisy corpus such as in clinical data, the text usually contains a large number of misspell words, abbreviations and acronyms that can be an obstacle to high quality information extraction and classification. Furthermore, the gold-standard training data needed for supervised learning usually contains many errors and inconsistencies due to differences in human annotators. In this research, a specialised proof-reading process for the clinical domain to resolve unknown tokens and convert scores and measures into a standard layout is introduced. The automatic coding of the texts increased the coded content significantly after the automatic correction process. Accuracy of the automatic coding and annotation of the notes which have not been coded by the clinical staff is suggested by the system output. To deal with the problem of noisy training data, this thesis proposes an algorithm for a method named “reverse active learning” which means applying active learning in reverse order to improve performance of supervised machine learning on clinical corpora. The effects of automatic proof-reading and reverse active learning are shown to produce results on the i2b2 2010 clinical corpus that are a state-of-the-art of supervised learning method and offer a means of improving all processing strategies in clinical language processing. Finally, a Cancer Staging Information Extraction System based on the combination of proposed methods of proof-reading, supervised learning, active learning and reverse active learning is presented. In this research, free-text reports are annotated for examples of the information to be extracted and then algorithms are developed that use the examples to compute a more general model of the desired content. Besides traditional supervised learning methods such as Conditional Random Fields and Support Vector Machines, active learning approaches are investigated to bring further improvement to information extraction system performance.
4
Bolton, Damien Michael. "Whole-of-population based studies In urologic cancer." Thesis, The University of Sydney, 2017. http://hdl.handle.net/2123/17066.
Full textAbstract:
Since Prostate Specific Antigen testing became commercially available prostate cancer has transformed from a clinically diagnosed often advanced disease usually in elderly men, to a biochemically detected usually organ confined condition which more often affects younger males. This resulted in a major shift in the patterns of care of prostate cancer from an observant, pharmaceutical therapy dominated algorithm, to surgically directed management via radical prostatectomy. This transition initially was undertaken on the basis of logic but with little conclusive evidence to support this change. It was this major adjustment in practice that was the impetus for this thesis. Few prospectively established whole-of–population registries of patients undergoing radical prostatectomy had been established at the time this project was conceived. The aim of this project was to follow sequentially for a 10 year period the progress of all men treated by radical prostatectomy in the state of Victoria, with a view to determining the likelihood of progression to objective biochemical and clinical benchmarks in the future. Multiple publications were derived from this registry, and from projects that have arisen as a consequence of the existence of the central database. Outcomes identified include the very low risk of prostate cancer specific mortality (PCSM) even after biochemical recurrence, especially in men with lower risk prostate cancer at diagnosis, and that predictors of PCSM independent of tumour stage and grade included rural residency of patients (p=.003), involvement of a trainee surgeon in the operation (p=.014), presentation with voiding symptoms rather than on the basis of an elevated PSA level, and the primary surgeon contributing less than 40 cases (low volume) to the VRPR (p=.024). As a consequence of the existence of our whole of population based registry of radical prostatectomy for prostate cancer the implications became apparent for patients of having a strong family history of breast cancer and of being a carrier of one or more variants of the BRCA gene. Extension of this concept resulted in a series of all men treated by High Intensity Focused Ultrasound (HIFU) upon its introduction in the state of Victoria, and a patterns of practice study of all patients in this state undergoing surgery for renal cell carcinoma.
5
Bin, Ishaq Saeed A. "Epidemiology of cancer as a tool to develop a population based cancer registry in the United Arab Emirates." Thesis, University of Glasgow, 2004. http://theses.gla.ac.uk/6197/.
Full textAbstract:
The purpose of this study was to assess the possibility of developing a population based cancer registry in the United Arab Emirates. As this was retrospective and explorative in nature, the study was performed in two stages, the initial stage where the researcher examined critically routinely collected data that is needed to support a cancer registry as well as assessed data on cancer that were obtained from Al Mafraq Hospital records. The final stage took place in Al Ain Medical District where detailed study of the existing practice with respect to cancer registration were undertaken in respond to a request form Ministry of Health, data on cancer were obtained from health care services and cancer registry records. Other information was obtained from key officials and health professionals in the district using qualitative methods. The initial stage showed that this was the first study of this kind in the United Arab Emirates and that cancer data production and recording is a complex intervention, where health and health related professionals and patients are involved. It also revealed that the key professionals were supportive to the study and showed positive attitude. The initial study indicated that there was deficiency in the data collected routinely as well as there was no cancer registry in Al-Mafraq Hospital. Furthermore, the data collected from medical record witnessed deficiency in their completeness and quality. Lack of education and training related to cancer data handling were observed during the fieldwork. The assessment of the population data sources indicated that there was no single data source that might provide a comprehensive and accurate data regarding Al Ain population. This condition was mainly created due to unique demographic pattern of a highly mobile population dominated by expatriates. The final stage showed that health facilities in Al Ain Medical District are capable of producing cancer data especially clinical data. However deficiencies in item definition, complete recording and storing of data by health professionals within the health facilities were identified.
6
Luo, Qingwei. "“Unknown” prostate cancer stage at diagnosis in a population-based cancer registry: impact on epidemiological studies and use of multiple imputation." Thesis, The University of Sydney, 2018. http://hdl.handle.net/2123/19948.
Full textAbstract:
Routinely collected population-based cancer registry stage data are crucial to inform health service planning and to monitor variations in cancer outcomes. However, incomplete stage information is a major concern due to potential biases this introduces. This thesis examined the reasons why a large proportion of prostate cancer cases are recorded as “unknown” stage in the New South Wales (NSW) Cancer Registry (NSWCR) and validated the multiple imputation (MI) method for dealing with “unknown” stage data. NSW is the most populous state in Australia, with almost one third of the total national population. The NSWCR is the only population-based cancer registry in Australia that has collected stage information since its inception in 1972. The usefulness of long-term historical cancer registry stage data when examining cancer outcomes is illustrated in Chapter 2, with an investigation of geographical variation in long-term survival over time. The research reported in Chapter 3 shows that prostate cancer cases with “unknown” stage differ from those with a known stage, as survival and risk of disease progression for cases with “unknown” stage was intermediate between those for cases with localised and regional disease. Several possible reasons that could contribute to why “unknown” stage is recorded in the NSWCR are identified in Chapter 4. The publication included in Chapter 5 shows that MI appears to be valid for “unknown” stage when the MI is implemented according to the practical guidelines recommended in the literature. The application of MI to the NSWCR “unknown” stage data reported in Chapter 6 shows that the imputed stage data appear to be reliable. These findings provide important insights into prostate cancer cases with “unknown” stage recorded in the NSWCR, and an understanding of the potential biases in epidemiological studies that use these data. The validated MI method to handle “unknown” stage will help to increase the utility of the cancer registry data.
7
Galvin, Angeline. "Accès aux soins et pronostic des personnes âgées atteintes d’un cancer : analyse des déterminants à partir de données issues de registres des cancers et de cohortes en Gironde." Thesis, Bordeaux, 2017. http://www.theses.fr/2017BORD0900/document.
Full textAbstract:
Le vieillissement de la population associé à un nombre croissant de cancers constituent une réalité épidémiologique qui soulève des interrogations sur l’accès aux soins et le pronosticdes sujets âgés avec un cancer, pour lesquels des disparités ont été mises en évidence. Toutefois, les études présentent plusieurs limites dont l’absence de facteurs spécifiques aux personnes âgées (PA). L’objectif de ce travail était d’étudier les déterminants sociodémographiques, socioéconomiques et cliniques de l’accès aux soins (stade de cancer, traitement) et du pronostic (déclin fonctionnel, survie) chez des PA atteintes d’un cancer. Les travaux ont été réalisés à partir de données issues de registres de cancers et de troiscohortes de PA en Gironde (486 patients de 65 ans et plus, période 2005-14). Les cohortes ont permis de disposer de données telles que le niveau d’éducation, le revenu, la prise demédicaments, la dépendance ou la démence. Selon l’objectif (accès/pronostic), nous avons utilisé différentes méthodes pour prendre en compte le type de données et de critères (régression logistique, modèles multiniveaux, modèles multi-état et de Cox). Notre population était composée pour plus de la moitié de PA de 80 ans et plus, de sexe masculin et ayant un niveau d’éducation supérieur au niveau primaire. Nous nous sommes d’abord intéressés aux déterminants de l’accès aux soins. Aucun déterminant d’un stade avancé de cancer au diagnostic n’a pu être mis en évidence, un niveau d’éducation faible était proche de la significativité pour les cancers avec un stade avancé (p=0,0671). Pour l’accès à un traitement du cancer, nous avons mis en évidence qu’un stade avancé (p=0,003) et la présence d’une démence (p=0,0109) étaient associés à un risque plus faible de recevoir un traitement. Nous avons ensuite étudié les déterminants du pronostic. Les sujets les plus âgés présentaient toujours un risque plus élevé de déclin fonctionnel (p<0,005), quel que soit le critère analysé. Les sujets ayant un faible niveau d’éducation (p=0,027), prenant plus de six médicaments par jour (p=0,047), présentant une démence (p<0,001) ou diagnostiqués à un stade avancé (p<0,001) avaient une probabilité de déclin fonctionnel plus importante, les résultats variant selon le critère. Enfin, à 12, 24 et 36 mois, la probabilité de survie globale était respectivement de 66, 57 et 48%. Le risque de décès était plus élevé chez les hommes (p=0,019), diagnostiqués à un stade avancé de cancer (p<0,001) et sans traitement du cancer (p<0,001), mais aussi chez les fumeurs (actuels et anciens) (p=0,019) et les PA dépendantes (p<0,001). En sus de déterminants classiques de l’accès aux soins ou du pronostic des cancers, nous avons mis en évidence pour les PA, le rôle des déficits cognitifs pour l’accès à un traitement ou sur le pronostic fonctionnel et celui de la dépendance sur la survie. Chez les PA avec un cancer, les facteurs spécifiques aux PA semblent donc essentiels à analyser. L’analyse des liens de causalité entre les déterminants de santé reste un sujet particulièrement intéressant dans cette population de PA comme pour les patients avec un cancerThe growing incidence of cancer associated to an aging population represents an epidemiologic reality that requires questioning access to care and prognosis in elderly with cancer, for which disparities have been highlighted. However, generally speaking, studies are limited in that they overlook geriatric-specific factors. The aim of this work was to study sociodemographic, socioeconomic and clinical determinants of access to care (cancer stage, cancer treatment) and prognosis (functional decline, survival) in elderly cancer patients. This research project has relied on data from cancer registries and three elderly cohort studies in the French department of Gironde (486 patients aged 65 and over from 2005 to 2014). The cohorts provided data such as education level, income, medication, dependency and dementia. Depending on the aim, we used different statistical methods to analyze different types of data and outcomes (logistic regression, multi-level model, multi-state model, Cox model). More than half of our population was aged 80 and over, male and had high education degrees. First, we studied determinants of access to care. No determinant of advance stage at diagnosis was found, but low education was close to significance for advanced stage (p=0.067). Concerning cancer treatment administration, advanced stage at diagnosis (p=0.003) and diagnosis of dementia (p=0.011) were associated with a lower risk of treatment administration. Second, we studied determinants of prognosis. Older old had higher risk of functional decline (p<0.001), regardless of the outcome. Subjects with low education (p=0.027), taking more than six daily drugs (0.047), presenting diagnosed dementia (p<0.001) or those with advanced cancer stage at diagnosis had higher risk of functional decline, results depending on outcome. At last, overall survival at 12, 24 and 36 months was 66, 55 and 48%, respectively. Risk of death was higher in men (p=0.019), in patients with advanced stage at diagnosis (p<0.001) or without treatment (p<0.001) in current and former smokers (p=0.019) and in dependent elderly patients (p<0.001). In addition to classical determinants of access to care and prognosis in cancer, we demonstrated the impact of cognitive impairment on treatment administration or functional prognosis, and that of dependency on survival. . It appears essential to consider geriatric specific factors in studies on the elderly with cancer population. The causality between health determinants is particularly interesting in the elderly as well as in the cancer populations
8
Wilson, Jodi. "Lifetime Physical Activity and the Risk of Colorectal Cancer: A Population-Based Case-Control Study Using Data from the Newfoundland Colorectal Cancer Registry." Thesis, Université d'Ottawa / University of Ottawa, 2016. http://hdl.handle.net/10393/34537.
Full textAbstract:
Although there is consistent evidence of an inverse association between physical activity and colorectal cancer (CRC), it is unclear whether physical activity has to be lifelong in order to protect against CRC, or whether there are critical time periods in which physical activity is most protective. This thesis investigated the association between recreational physical activities in specific age periods and across the lifetime and CRC risk in data from a population-based case control study (n=1395) in Newfoundland and Labrador. There were no significant associations between recreational physical activity at any age period or across the lifetime. Lack of association with activity in early adulthood is consistent with other studies in which this has been investigated. Lack of association in later life and across the lifetime may in part be explained by low levels of recreational physical activity, with only 30% of participants meeting World Cancer Research Fund cancer prevention recommendations.
9
Tanaka, Luana Fiengo. "A epidemiologia do câncer em crianças e adolescentes com Aids no Município de São Paulo: um estudo de base populacional." Universidade de São Paulo, 2017. http://www.teses.usp.br/teses/disponiveis/6/6132/tde-18042017-150014/.
Full textAbstract:
Introdução: A associação entre a infecção pelo vírus da imunodeficiência humana (HIV) e o câncer tem sido documentada desde os primórdios da epidemia da síndrome da imunodeficiência adquirida (Aids). A introdução da highly active antirretroviral therapy (HAART) alterou, profundamente, o curso da epidemia da Aids, reduzindo, drasticamente, a incidência de manifestações definidoras da síndrome, incluindo cânceres. No entanto, existem informações limitadas sobre a incidência de câncer em crianças e adolescentes com Aids vivendo em países em desenvolvimento. Objetivo: Descrever a epidemiologia do câncer em crianças e adolescentes com Aids no Município de São Paulo, no período de 1997 a 2012. Métodos: Trata-se de um estudo de base populacional, utilizando as bases de dados do Registro de Câncer de Base Populacional do Município de São Paulo e do Sistema de Informações de Agravos de Notificação (SINAN). As crianças e adolescentes (< 20 anos) com Aids e câncer foram identificadas por meio de um processo de linkage probabilístico entre as bases de dados supracitadas. Foram calculadas as taxas de incidência brutas e ajustadas por milhão de habitantes. Para comparar a incidência de câncer na população com Aids e a população geral foi calculada a razão de incidência padronizada (RIP) e respectivos intervalos de confiança de 95 por cento (IC 95 por cento ). A análise de tendência foi feita por meio do cálculo do annual percent change (APC) e IC 95 por cento correspondentes. A análise da sobrevida global de cinco anos após o câncer entre pacientes com Aids e na população geral foi calculada por meio do estimador produto limite de Kaplan-Meier e modelos univariados de riscos proporcionais de Cox. Mapas coropléticos em escalas monocromáticas foram gerados para descrever a distribuição de casos no Município. Resultados: Foram identificados 24 casos de câncer em pacientes com Aids menores de 20 anos, sendo 62,5 por cento cânceres definidores de Aids. Os cânceres mais incidentes foram o linfoma não Hodgkin, incluindo o linfoma de Burkitt (12; 50,0 por cento ), o linfoma de Hodgkin (6; 25,0 por cento ) e o sarcoma de Kaposi (3; 12,5 por cento ). A taxa bruta de incidência foi de 1.461,3 casos/milhão. A análise de tendência revelou redução significativa da incidência para todos os cânceres (APC= -14,5), influenciada pela queda nos cânceres definidores de Aids (APC= -17,0). O risco para câncer se mostrou aumentado (RIP= 3,9), sobretudo para o linfoma não Hodgkin, excluindo linfoma de Burkitt (RIP= 22,5), linfoma de Burkitt (RIP= 29,7) e linfoma de Hodgkin (RIP= 18,7). A probabilidade acumulada de sobrevida aos cinco anos foi de 56,3 por cento em crianças e adolescentes com Aids versus 87,5 por cento na população geral. A hazard ratio para óbito foi 5,2 (IC 95 por cento = 2,0; 13,6). O mapa da distribuição geográfica mostrou concentração dos casos nas áreas de classes sociais mais baixas do Município. Conclusão: Houve redução acentuada da incidência de cânceres definidores de Aids, como provável resultado da introdução da HAART. No entanto, crianças e adolescentes com Aids permanecem sob risco aumentado para o desenvolvimento de câncer quando comparadas à população geral. Para aquelas que desenvolveram câncer, o risco para óbito também se mostrou substancialmente elevadoIntroduction: The association between human immunodeficiency virus (HIV) infection and cancer has been documented since the beginning of the epidemic of the acquired immunodeficiency syndrome (AIDS). The introduction of the highly active antiretroviral therapy (HAART) has profoundly altered the course of the AIDS epidemic, drastically reducing the incidence of AIDS-defining manifestations, including cancers. Nevertheless, there is limited information on the incidence of cancer in children and adolescents with AIDS living in developing countries. Objective: To describe the cancer epidemiology in children and adolescents with AIDS in the Municipality of São Paulo from 1997 to 2012. Methods: It is a population-based study, using the databases of the Population-based Cancer Registry of São Paulo and the Notifiable Diseases Information System (SINAN). Children and adolescents (< 20 years) with AIDS and cancer have been identified by means of a probabilistic record linkage process between the aforementioned databases. Crude and age-standardized incidence rates per million inhabitants were calculated. To compare the incidence of cancer in people with AIDS and that of the general population, standardized incidence ratio (SIR) and respective 95 per cent confidence intervals (95 per cent CI) were calculated. We examined trends by calculating the annual percent change (APC) and corresponding 95 per cent CI. The analyses of the overall five-year survival after cancer diagnosis among children and adolescents with AIDS and that of the general population were based on the Kaplan-Meier product limit estimator and univariate Cox proportional hazards models. Choropleth maps on monochromatic scales were generated to describe the distribution of cases across the Municipality. Results: We identified 24 cases of cancer in patients with AIDS aged 20 years and younger, of which, 62.5 per cent were AIDS-defining malignancies. The most incident cancers were non-Hodgkin\'s lymphoma, including Burkitt\'s lymphoma (12; 50.0 per cent ), Hodgkin\'s lymphoma (6; 25.0 per cent ) and Kaposi sarcoma (3; 12.5 per cent ). The age-standardized incidence rate was 1,461.3 cases/million. The trend analyses revealed a significant reduction in the incidence of all cancers (APC= -14.5), driven by the decrease in AIDS-defining cancers (APC= -17.0). The overall risk for cancer was significantly increased (SIR= 3.9), especially for non-Hodgkin lymphoma, excluding Burkitts lymphoma (SIR= 22.5), Burkitt\'s lymphoma (SIR= 29.7) and Hodgkin\'s lymphoma (SIR= 18.7). The overall probability of survival at five years after cancer was 56.3 per cent in children and adolescents with AIDS versus 87.5 per cent in the general population. The hazard ratio for death was 5.2 (95 per cent CI= 2.0, 13.6). The map of the geographical distribution showed a concentration of cases in the low-income areas of the Municipality. Conclusion: There was a marked reduction in the incidence of AIDS-defining cancers, likely to be a result of the introduction of HAART. However, children and adolescents with AIDS remain at increased risk for the development of cancer when compared to the general population. For those who developed cancer, the risk of death was also significantly higher
10
Peres, Stela Verzinhasse. "Uso da técnica de linkage nos sistemas de informação em saúde: aplicação na base de dados do Registro de Câncer de base populacional do município de São Paulo." Universidade de São Paulo, 2011. http://www.teses.usp.br/teses/disponiveis/6/6132/tde-27032012-173312/.
Full textAbstract:
A disponibilidade de grandes bases de dados informatizadas em saúde tornou a técnica de relacionamento de fontes de dados, também conhecida como linkage, uma alternativa para diferentes tipos de estudos. Esta técnica proporciona a geração de uma base de dados mais completa e de baixo custo operacional. Objetivo- Investigar a possibilidade de completar/aperfeiçoar as informações da base de dados do RCBP-SP, no período de 1997 a 2005, utilizando o processo de linkage com três outras bases, a saber: Programa de Aprimoramento de Mortalidade (PRO-AIM), Autorização e Procedimentos de Alta Complexidade (APAC-SIA/SUS) e Fundação Sistema Estadual de Análise de Dados (FSeade). Métodos- Neste estudo foi utilizada a base de dados do RCBP-SP, composta por 343.306 com casos incidentes de câncer do município de São Paulo, registrados no período de 1997 a 2005, com idades que variaram de menos de um a 106 anos, de ambos os sexos. Para a completitude das informações do RCBP-SP foram utilizadas as bases de dados, a saber: PRO-AIM, APAC-SIA/SUS e FSeade. Foram utilizadas as técnicas de linkage probabilística e determinística. O linkage probabilístico foi realizado pelo programa Reclink III versão 3.1.6. Quanto ao linkage determinístico as rotinas foram realizadas em Visual Basic, com as bases hospedadas em SQL Server. Foram calculados os coeficientes brutos de incidência (CBI) e mortalidade (CBM) antes e após o linkage. A análise de sobrevida global foi realizada pela técnica de Kaplan-Meier e para na comparação entre as curvas, utilizou-se o teste de log rank. Foram calculados os valores da área sob a curva, sensibilidade e especificidade para determinar o ponto de corte do escore de maior precisão na identificação dos pares verdadeiros. Resultados- Após o linkage, verificou-se um ganho de 101,5 por cento para a variável endereço e 31,5 por cento para a data do óbito e 80,0 por cento para a data da última informação. Quanto à variável nome da mãe, na base de dados do RCBP-SP antes do linkage esta informação representava somente 0,5 por cento , tendo sido complementada, no geral, em 76.332 registros. A análise de sobrevida global mostrou que antes do processo de linkage havia uma subestimação na probabilidade de estar vivo em todos os períodos analisados. No geral, para a análise de sobrevida truncada em sete anos, a probabilidade de estar vivo no primeiro ano de seguimento antes do linkage foi menor quando comparada a probabilidade de estar vivo ao primeiro ano de seguimento após o linkage (48,8 por cento x 61,1 por cento ; p< 0,001). Conclusão- A técnica de linkage tanto probabilística quanto determinística foi efetiva para completar/aperfeiçoar as informações da base de dados do RCBP-SP. Além do mais, o CBI apresentou um ganho de 3,4 por cento . Quanto ao CBM houve um ganho de 25,8 por cento . Após o uso da técnica de linkage, foi verificado que os valores para a sobrevida global estavam subestimados para ambos os sexos, faixas etárias e para as topografias de câncerThe availability of large computerized databases on health has enabled the record linkage technique, an alternative for different study designs. This technique provides the generation of a more complete database, at low operational cost. Objective to investigate the possibility of completing/improving information from the database of the RCBP-SP, in the period between 1997 and 2005, using the record linkage technique with other three databases, namely: Mortality Improvement Program (PRO-AIM), Authorization of Highly Complex Procedures (APAC-SIA/SUS) and State System of Data Analysis (FSeade), comparing different strategies. Methods In this study we used the database of the RCBP-SP composed of 343,306 incident cancer cases in the Municipality of São Paulo registered in the period between 1997 and 2005 with ages raging from under one to 106 years, from both sexes. To complete the database of the RCBP-SP three databases were used, namely: PRO-AIM, APAC-SIA/SUS and FSeade. Both probabilistic and deterministic record linkage were used. Probabilistic linkage was performed using the Reclink III software, version 3.1.6. As for the the deterministic record linkage, the routines were run in the Visual Basic and databases hosted on a SQL Server. Before and after record linkage, crude incidence (CIR) and mortality rates (CMR) were calculated. The overall survival analysis was performed using the Kaplan-Meier technique and for the comparison between curves, the log rank test was employed. In order to determine the most precise cut-off scores in identifying true matches, we calculated the area under the curve, as well as, sensitivity and specificity. Results After record linkage, it was verified a gain of 101.5 per cent for the variable address, 31.5 per cent for death date and 80,0 per cent for the date of latest information. As for the variable mother´s name, in the database of the RCBP-SP before record linkage, this information represented only 0.5 per cent , having been completed, in general, in 76,332 registries. The overall survival analysis showed that before the record linkage there was an underestimation of the probability of being alive for all periods assessed. In general, for the truncated survival at seven years, the probability of being alive at the first year of follow up before record linkage was lower when compared to the probability of being alive at the first year of follow up after record linkage (48.8 per cent x 61.1 per cent ; p< 0.001). Conclusion Both the probabilistic and deterministic record linkage were effective to complete/improve information from the database of the RCBP-SP. Moreover, the CIR had a gain of de 3.4 per cent . As for the CMR, there was a gain of 25.8 per cent . After using the record linkage technique, it was verified that values for overall survival were underestimated for both sexes, all age groups, and cancer sites
Books on the topic "Population-based cancer registry"
1
Merabishvili, V. M. Onkologicheskai︠a︡ sluzhba v Sankt-Peterburge i raĭonakh goroda v 2009 godu: Ezhegodnik Populi︠a︡t︠s︡ionnogo rakovogo registra = Cancer incidence in St. Petersburg and city districts in 2009 Express information of the Population-based Cancer Registry. Sankt-Peterburg: IPK "KOSTA", 2010.
Find full text
2
1925-, Tokuhata George Kazunari, ed. TMI population registry-based cohort cancer incidence, July 1982-June 1989. Harrisburg, PA: Division of Epidemiology Research, Pennsylvania Dept. of Health, 1991.
Find full text
3
Dr, Rajan B., Mathew Aleyamma, and Regional Cancer Centre (Trivandrum, India), eds. Cancer incidence and mortality: Population based cancer registry : Thiruvananthapuram (urban & rural) : two-year report, 2001-2002. Thiruvananthapuram: Regional Cancer Centre, 2005.
Find full text
4
Krishnan, Ramaswamy, ed. Three Mile Island (TMI) population registry-based cohort mortality: 1979-1985 period. Harrisburg, Pa: Division of Epidemiology Research, Bureau of Epidemiology and Disease Prevention, Pennsylvania Department of Health, 1989.
Find full text
5
Bhopal, Raj S. Epidemiological study designs and principles of data analysis: A conceptually integrated suite of methods and techniques. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780198739685.003.0009.
Full textAbstract:
Epidemiological studies are unified by their common goals and by their basis in defined populations. The case series (or register-based study) includes examination of trends in deaths, cancers, notifiable diseases, and hospitalizations. Case–control studies are analysed by comparing the exposure to risk factors in cases to those in controls. In a population studied at a specific time and place (a cross-sectional study), measurements can be made of disease, the factors which may cause disease, or both simultaneously. Cohort studies produce data on disease incidence and are especially good on associations between risk factors and disease outcomes. Trials compare treated and untreated populations and are used, primarily, for information on effectiveness of health interventions. Natural experiments, including Mendelian randomization studies, may provide causal evidence. The principles for the analysis of all studies are similar. The design and interpretation should be in the context of traditional, systematic, and meta-analytic reviews.
Book chapters on the topic "Population-based cancer registry"
1
Band, P. R., J. J. Spinelli, R. P. Gallagher, W. J. Threlfall, V. T. Y. Ng, J. Moody, D. Raynor, L. M. Svirchev, D. Kan, and M. Wong. "Identification of Occupational Cancer Risks Using a Population-Based Cancer Registry." In Occupational Cancer Epidemiology, 106–21. Berlin, Heidelberg: Springer Berlin Heidelberg, 1990. http://dx.doi.org/10.1007/978-3-642-84068-5_8.
Full text
2
Takano, Akira, and Yoshi Okuno. "End Results of Cancer Patients: From Population-Based Cancer Registry Data." In Changing Cancer Patterns and Topics in Cancer Epidemiology, 81–87. Boston, MA: Springer US, 1987. http://dx.doi.org/10.1007/978-1-4684-1288-8_8.
Full text
3
Kehoe, Thomas. "New Possibilities: The VCR as a Population-Based Registry, 1981–1990." In Cancer Data For Good, 89–111. Singapore: Springer Nature Singapore, 2022. http://dx.doi.org/10.1007/978-981-19-4987-6_5.
Full text
4
Prodhan, Sujohn, Mary Jane King, Prithwish De, and Julie Gilbert. "Health Services Data: The Ontario Cancer Registry (a Unique, Linked, and Automated Population-Based Registry)." In Health Services Evaluation, 363–90. New York, NY: Springer US, 2019. http://dx.doi.org/10.1007/978-1-4939-8715-3_18.
Full text
5
Prodhan, Sujohn, Mary Jane King, Prithwish De, and Julie Gilbert. "Health Services Data: The Ontario Cancer Registry (a Unique, Linked, and Automated Population-Based Registry)." In Data and Measures in Health Services Research, 1–27. Boston, MA: Springer US, 2016. http://dx.doi.org/10.1007/978-1-4899-7673-4_18-1.
Full text
6
Prodhan, Sujohn, Mary Jane King, Prithwish De, and Julie Gilbert. "Health Services Data: The Ontario Cancer Registry (a Unique, Linked, and Automated Population-Based Registry)." In Data and Measures in Health Services Research, 1–28. Boston, MA: Springer US, 2016. http://dx.doi.org/10.1007/978-1-4899-7673-4_18-2.
Full text
7
Mehdi, Itrat, Abdul Aziz Al Farsi, Bassim Al Bahrani, and Shadha S. Al-Raisi. "General Oncology Care in Oman." In Cancer in the Arab World, 175–93. Singapore: Springer Singapore, 2022. http://dx.doi.org/10.1007/978-981-16-7945-2_12.
Full textAbstract:
AbstractThe Sultanate of Oman is located on the Arabian Peninsula and is part of Western Asia. Oman has a relatively young population. The economy is based on oil, agriculture, fishing, and overseas trading. Oman spends around 3% of its GDP on health care. Omani nationals have free access to public healthcare. Due to increased incomes and changing lifestyles, the rate of Non-Communicable Diseases (NCD) including cancer is rising. This is slowly saturating the system and increasing health care costs. Cancer is now the third leading cause of mortality. The age-adjusted annual incidence of cancer ranges from 70 to 110 per 100,000 population. Oman has an operational national NCD action plan. This multi-sectoral plan was launched in 2018 and focuses on the government approach in addressing NCDs including cancer, highlighting the prevention and control strategies. There is an integrated cancer care service, cancer registry, and cancer control program; under the auspices of the Directorate general of Non-communicable diseases—Ministry of Health. Oman has envisioned an ambitious long-term health care plan called “Health care Vision 2050”, which includes the development and progression of cancer care services as well. This plan has an emphasis on development, patient empowerment, public awareness, health education, integration and accessibility of services, screening, and early detection, public–private partnership, indulgence for NGOs, research, and capacity building.
8
Yu, Binbing. "Real-World Evidence from Population-Based Cancer Registry Data." In Real-World Evidence in Drug Development and Evaluation, 47–70. Chapman and Hall/CRC, 2021. http://dx.doi.org/10.1201/9780429398674-3.
Full text
9
Nicholson, Nicholas, Francesco Giusti, Luciana Neamtiu, Giorgia Randi, Tadeusz Dyba, Manola Bettio, Raquel Negrao Carvalho, Nadya Dimitrova, Manuela Flego, and Carmen Martos. "Dotting the “i” of Interoperability in FAIR Cancer-Registry Data Sets." In Biomedical Engineering. IntechOpen, 2021. http://dx.doi.org/10.5772/intechopen.101330.
Full textAbstract:
To conform to FAIR principles, data should be findable, accessible, interoperable, and reusable. Whereas tools exist for making data findable and accessible, interoperability is not straightforward and can limit data reusability. Most interoperability-based solutions address semantic description and metadata linkage, but these alone are not sufficient for the requirements of inter-comparison of population-based cancer data, where strict adherence to data-rules is of paramount importance. Ontologies, and more importantly their formalism in description logics, can play a key role in the automation of data-harmonization processes predominantly via the formalization of the data validation rules within the data-domain model. This in turn leads to a potential quality metric allowing users or agents to determine the limitations in the interpretation and comparability of the data. An approach is described for cancer-registry data with practical examples of how the validation rules can be modeled with description logic. Conformance of data to the rules can be quantified to provide metrics for several quality dimensions. Integrating these with metrics derived for other quality dimensions using tools such as data-shape languages and data-completion tests builds up a data-quality context to serve as an additional component in the FAIR digital object to support interoperability in the wider sense.
Conference papers on the topic "Population-based cancer registry"
1
Nguyen, Dung H. M., and Jon D. Patrick. "Information Extraction from Radiology Reports for a Population based Cancer Registry." In Biomedical Engineering. Calgary,AB,Canada: ACTAPRESS, 2013. http://dx.doi.org/10.2316/p.2013.791-046.
Full text
2
Stirling, Robert G., Peta McLaughlin, Meera Senthuren, Sue Evans, D. N. Watkins, and J. J. McNeil. "Quality In Lung Cancer Care: The Development Of A Population Based Lung Cancer Registry." In American Thoracic Society 2012 International Conference, May 18-23, 2012 • San Francisco, California. American Thoracic Society, 2012. http://dx.doi.org/10.1164/ajrccm-conference.2012.185.1_meetingabstracts.a5142.
Full text
3
Tanjak, Pariyada, Benjarat Thiengtrong, Kanokporn Thamapala, Tippawan Gerdsuriwong, Cholticha Songjang, Aem-on Rattanakumnerd, Onchira Acharayothin, et al. "Abstract 5767: Multiple primary cancer from a retrospective population-based cancer registry, 1991 through 2015." In Proceedings: AACR Annual Meeting 2020; April 27-28, 2020 and June 22-24, 2020; Philadelphia, PA. American Association for Cancer Research, 2020. http://dx.doi.org/10.1158/1538-7445.am2020-5767.
Full text
4
Buttmann-Schweiger, N., B. Barnes, H. Woopen, I. Braicu, K. Pietzner, and J. Sehouli. "Retrospective study of long-term epithelial ovarian cancer survivors: clinical data and population-based cancer registry data." In Gemeinsam forschen – gemeinsam handeln. Georg Thieme Verlag KG, 2017. http://dx.doi.org/10.1055/s-0037-1606027.
Full text
5
Gennari, P., A. Ignatov, M. Gerken, and O. Ortmann. "Minimally invasive vs open hysterectomy for the treatment of early cervical cancer retrospective population-based cancer registry study." In Kongressabstracts zur Tagung 2020 der Deutschen Gesellschaft für Gynäkologie und Geburtshilfe (DGGG). © 2020. Thieme. All rights reserved., 2020. http://dx.doi.org/10.1055/s-0040-1718136.
Full text
6
"MODEL-DRIVEN AD HOC DATA INTEGRATION IN THE CONTEXT OF A POPULATION-BASED CANCER REGISTRY." In Special Session on Data Management and Information Analytics. SciTePress - Science and and Technology Publications, 2010. http://dx.doi.org/10.5220/0003044703370343.
Full text
7
Picado, Omar, Jordan Baeker-Bispo, Layla Bouzoubaa, Raymond R. Balise, Gilberto Lopes, and Erin N. Kobetz. "Abstract C056: Cancer patterns and trends in Costa Rica: A population-based tumor registry study." In Abstracts: Eleventh AACR Conference on The Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; November 2-5, 2018; New Orleans, LA. American Association for Cancer Research, 2020. http://dx.doi.org/10.1158/1538-7755.disp18-c056.
Full text
8
Moubadder, Leah, Audrey Chang, Kevin C. Ward, and Timothy L. Lash. "Abstract 4188: Registering cancer recurrence in a population-based registry: The value of pathology data." In Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.sabcs18-4188.
Full text
9
Moubadder, Leah, Audrey Chang, Kevin C. Ward, and Timothy L. Lash. "Abstract 4188: Registering cancer recurrence in a population-based registry: The value of pathology data." In Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.am2019-4188.
Full text
10
Lu, Sai San Moon, Zahraa Mohammed, Christel Häggström, Robin Myte, Elisabeth Lindquist, Åsa Gylfe, Bethany Van Guelpen, and Sophia Harlid. "Abstract 1055: Antibiotic use and risk of colorectal cancer: A Swedish population-based registry study." In Proceedings: AACR Annual Meeting 2020; April 27-28, 2020 and June 22-24, 2020; Philadelphia, PA. American Association for Cancer Research, 2020. http://dx.doi.org/10.1158/1538-7445.am2020-1055.
Full textReports on the topic "Population-based cancer registry"
1
Rankin, Nicole, Deborah McGregor, Candice Donnelly, Bethany Van Dort, Richard De Abreu Lourenco, Anne Cust, and Emily Stone. Lung cancer screening using low-dose computed tomography for high risk populations: Investigating effectiveness and screening program implementation considerations: An Evidence Check rapid review brokered by the Sax Institute (www.saxinstitute.org.au) for the Cancer Institute NSW. The Sax Institute, October 2019. http://dx.doi.org/10.57022/clzt5093.
Full textAbstract:
Background Lung cancer is the number one cause of cancer death worldwide.(1) It is the fifth most commonly diagnosed cancer in Australia (12,741 cases diagnosed in 2018) and the leading cause of cancer death.(2) The number of years of potential life lost to lung cancer in Australia is estimated to be 58,450, similar to that of colorectal and breast cancer combined.(3) While tobacco control strategies are most effective for disease prevention in the general population, early detection via low dose computed tomography (LDCT) screening in high-risk populations is a viable option for detecting asymptomatic disease in current (13%) and former (24%) Australian smokers.(4) The purpose of this Evidence Check review is to identify and analyse existing and emerging evidence for LDCT lung cancer screening in high-risk individuals to guide future program and policy planning. Evidence Check questions This review aimed to address the following questions: 1. What is the evidence for the effectiveness of lung cancer screening for higher-risk individuals? 2. What is the evidence of potential harms from lung cancer screening for higher-risk individuals? 3. What are the main components of recent major lung cancer screening programs or trials? 4. What is the cost-effectiveness of lung cancer screening programs (include studies of cost–utility)? Summary of methods The authors searched the peer-reviewed literature across three databases (MEDLINE, PsycINFO and Embase) for existing systematic reviews and original studies published between 1 January 2009 and 8 August 2019. Fifteen systematic reviews (of which 8 were contemporary) and 64 original publications met the inclusion criteria set across the four questions. Key findings Question 1: What is the evidence for the effectiveness of lung cancer screening for higher-risk individuals? There is sufficient evidence from systematic reviews and meta-analyses of combined (pooled) data from screening trials (of high-risk individuals) to indicate that LDCT examination is clinically effective in reducing lung cancer mortality. In 2011, the landmark National Lung Cancer Screening Trial (NLST, a large-scale randomised controlled trial [RCT] conducted in the US) reported a 20% (95% CI 6.8% – 26.7%; P=0.004) relative reduction in mortality among long-term heavy smokers over three rounds of annual screening. High-risk eligibility criteria was defined as people aged 55–74 years with a smoking history of ≥30 pack-years (years in which a smoker has consumed 20-plus cigarettes each day) and, for former smokers, ≥30 pack-years and have quit within the past 15 years.(5) All-cause mortality was reduced by 6.7% (95% CI, 1.2% – 13.6%; P=0.02). Initial data from the second landmark RCT, the NEderlands-Leuvens Longkanker Screenings ONderzoek (known as the NELSON trial), have found an even greater reduction of 26% (95% CI, 9% – 41%) in lung cancer mortality, with full trial results yet to be published.(6, 7) Pooled analyses, including several smaller-scale European LDCT screening trials insufficiently powered in their own right, collectively demonstrate a statistically significant reduction in lung cancer mortality (RR 0.82, 95% CI 0.73–0.91).(8) Despite the reduction in all-cause mortality found in the NLST, pooled analyses of seven trials found no statistically significant difference in all-cause mortality (RR 0.95, 95% CI 0.90–1.00).(8) However, cancer-specific mortality is currently the most relevant outcome in cancer screening trials. These seven trials demonstrated a significantly greater proportion of early stage cancers in LDCT groups compared with controls (RR 2.08, 95% CI 1.43–3.03). Thus, when considering results across mortality outcomes and early stage cancers diagnosed, LDCT screening is considered to be clinically effective. Question 2: What is the evidence of potential harms from lung cancer screening for higher-risk individuals? The harms of LDCT lung cancer screening include false positive tests and the consequences of unnecessary invasive follow-up procedures for conditions that are eventually diagnosed as benign. While LDCT screening leads to an increased frequency of invasive procedures, it does not result in greater mortality soon after an invasive procedure (in trial settings when compared with the control arm).(8) Overdiagnosis, exposure to radiation, psychological distress and an impact on quality of life are other known harms. Systematic review evidence indicates the benefits of LDCT screening are likely to outweigh the harms. The potential harms are likely to be reduced as refinements are made to LDCT screening protocols through: i) the application of risk predication models (e.g. the PLCOm2012), which enable a more accurate selection of the high-risk population through the use of specific criteria (beyond age and smoking history); ii) the use of nodule management algorithms (e.g. Lung-RADS, PanCan), which assist in the diagnostic evaluation of screen-detected nodules and cancers (e.g. more precise volumetric assessment of nodules); and, iii) more judicious selection of patients for invasive procedures. Recent evidence suggests a positive LDCT result may transiently increase psychological distress but does not have long-term adverse effects on psychological distress or health-related quality of life (HRQoL). With regards to smoking cessation, there is no evidence to suggest screening participation invokes a false sense of assurance in smokers, nor a reduction in motivation to quit. The NELSON and Danish trials found no difference in smoking cessation rates between LDCT screening and control groups. Higher net cessation rates, compared with general population, suggest those who participate in screening trials may already be motivated to quit. Question 3: What are the main components of recent major lung cancer screening programs or trials? There are no systematic reviews that capture the main components of recent major lung cancer screening trials and programs. We extracted evidence from original studies and clinical guidance documents and organised this into key groups to form a concise set of components for potential implementation of a national lung cancer screening program in Australia: 1. Identifying the high-risk population: recruitment, eligibility, selection and referral 2. Educating the public, people at high risk and healthcare providers; this includes creating awareness of lung cancer, the benefits and harms of LDCT screening, and shared decision-making 3. Components necessary for health services to deliver a screening program: a. Planning phase: e.g. human resources to coordinate the program, electronic data systems that integrate medical records information and link to an established national registry b. Implementation phase: e.g. human and technological resources required to conduct LDCT examinations, interpretation of reports and communication of results to participants c. Monitoring and evaluation phase: e.g. monitoring outcomes across patients, radiological reporting, compliance with established standards and a quality assurance program 4. Data reporting and research, e.g. audit and feedback to multidisciplinary teams, reporting outcomes to enhance international research into LDCT screening 5. Incorporation of smoking cessation interventions, e.g. specific programs designed for LDCT screening or referral to existing community or hospital-based services that deliver cessation interventions. Most original studies are single-institution evaluations that contain descriptive data about the processes required to establish and implement a high-risk population-based screening program. Across all studies there is a consistent message as to the challenges and complexities of establishing LDCT screening programs to attract people at high risk who will receive the greatest benefits from participation. With regards to smoking cessation, evidence from one systematic review indicates the optimal strategy for incorporating smoking cessation interventions into a LDCT screening program is unclear. There is widespread agreement that LDCT screening attendance presents a ‘teachable moment’ for cessation advice, especially among those people who receive a positive scan result. Smoking cessation is an area of significant research investment; for instance, eight US-based clinical trials are now underway that aim to address how best to design and deliver cessation programs within large-scale LDCT screening programs.(9) Question 4: What is the cost-effectiveness of lung cancer screening programs (include studies of cost–utility)? Assessing the value or cost-effectiveness of LDCT screening involves a complex interplay of factors including data on effectiveness and costs, and institutional context. A key input is data about the effectiveness of potential and current screening programs with respect to case detection, and the likely outcomes of treating those cases sooner (in the presence of LDCT screening) as opposed to later (in the absence of LDCT screening). Evidence about the cost-effectiveness of LDCT screening programs has been summarised in two systematic reviews. We identified a further 13 studies—five modelling studies, one discrete choice experiment and seven articles—that used a variety of methods to assess cost-effectiveness. Three modelling studies indicated LDCT screening was cost-effective in the settings of the US and Europe. Two studies—one from Australia and one from New Zealand—reported LDCT screening would not be cost-effective using NLST-like protocols. We anticipate that, following the full publication of the NELSON trial, cost-effectiveness studies will likely be updated with new data that reduce uncertainty about factors that influence modelling outcomes, including the findings of indeterminate nodules. Gaps in the evidence There is a large and accessible body of evidence as to the effectiveness (Q1) and harms (Q2) of LDCT screening for lung cancer. Nevertheless, there are significant gaps in the evidence about the program components that are required to implement an effective LDCT screening program (Q3). Questions about LDCT screening acceptability and feasibility were not explicitly included in the scope. However, as the evidence is based primarily on US programs and UK pilot studies, the relevance to the local setting requires careful consideration. The Queensland Lung Cancer Screening Study provides feasibility data about clinical aspects of LDCT screening but little about program design. The International Lung Screening Trial is still in the recruitment phase and findings are not yet available for inclusion in this Evidence Check. The Australian Population Based Screening Framework was developed to “inform decision-makers on the key issues to be considered when assessing potential screening programs in Australia”.(10) As the Framework is specific to population-based, rather than high-risk, screening programs, there is a lack of clarity about transferability of criteria. However, the Framework criteria do stipulate that a screening program must be acceptable to “important subgroups such as target participants who are from culturally and linguistically diverse backgrounds, Aboriginal and Torres Strait Islander people, people from disadvantaged groups and people with a disability”.(10) An extensive search of the literature highlighted that there is very little information about the acceptability of LDCT screening to these population groups in Australia. Yet they are part of the high-risk population.(10) There are also considerable gaps in the evidence about the cost-effectiveness of LDCT screening in different settings, including Australia. The evidence base in this area is rapidly evolving and is likely to include new data from the NELSON trial and incorporate data about the costs of targeted- and immuno-therapies as these treatments become more widely available in Australia.
2
Skelly, Andrea C., Roger Chou, Joseph R. Dettori, Erika D. Brodt, Andrea Diulio-Nakamura, Kim Mauer, Rongwei Fu, et al. Integrated and Comprehensive Pain Management Programs: Effectiveness and Harms. Agency for Healthcare Research and Quality (AHRQ), October 2021. http://dx.doi.org/10.23970/ahrqepccer251.
Full textAbstract:
Objectives. To evaluate the effectiveness and harms of pain management programs that are based on the biopsychosocial model of care, particularly in the Medicare population. Data sources. Electronic databases (Ovid® MEDLINE®, PsycINFO®, CINAHL®, Cochrane Central Register of Controlled Trials, and Cochrane Database of Systematic Reviews) from 1989 to May 24, 2021; reference lists; and a Federal Register notice. Review methods. Given lack of consensus on terminology and program definition for pain management, we defined programs as integrated (based in and integrated with primary care) and comprehensive (referral based and separate from primary care) pain management programs (IPMPs and CPMPs). Using predefined criteria and dual review, we selected randomized controlled trials (RCTs) comparing IPMPs and CPMPs with usual care or waitlist, physical activity, pharmacologic therapy, and psychological therapy in patients with complex acute/subacute pain or chronic nonactive cancer pain. Patients needed to have access to medication support/review, psychological support, and physical function support in programs. Meta-analyses were conducted to improve estimate precision. We classified the magnitude of effects as small, moderate, or large based on predefined criteria. Strength of evidence (SOE) was assessed for the primary outcomes of pain, function, and change in opioid use. Results. We included 57 RCTs; 8 evaluated IPMPs and 49 evaluated CPMPs. Compared with usual care or waitlist, IPMPs were associated with small improvements in pain in the short and intermediate term (SOE: low) and in function in the short term (SOE: moderate), but there were no clear differences at other time points. CPMPs were associated with small improvements in pain immediately postintervention (SOE: moderate) but no differences in the short, intermediate, and long term (SOE: low); for function, improvements were moderate immediately postintervention and in the short term; there were no differences in the intermediate or long term (SOE: low at all time points). CPMPs were associated with small to moderate improvements in function and pain versus pharmacologic treatment alone at multiple time frames (SOE: moderate for function intermediate term; low for pain and function at all other times), and with small improvements in function but no improvements in pain in the short term when compared with physical activity alone (SOE: moderate). There were no differences between CPMPs and psychological therapy alone at any time (SOE: low). Serious harms were not reported, although evidence on harms was insufficient. The mean age was 57 years across IPMP RCTs and 45 years across CPMP RCTs. None of the trials specifically enrolled Medicare beneficiaries. Evidence on factors related to program structure, delivery, coordination, and components that may impact outcomes is sparse and there was substantial variability across studies on these factors. Conclusions. IPMPs and CPMPs may provide small to moderate improvements in function and small improvements in pain in patients with chronic pain compared with usual care. Formal pain management programs have not been widely implemented in the United States for general populations or the Medicare population. To the extent that programs are tailored to patients’ needs, our findings are potentially applicable to the Medicare population. Programs that address a range of biopsychosocial aspects of pain, tailor components to patient need, and coordinate care may be of particular importance in this population.